Cargando…

Renal impairment associated with tenofovir disoproxil fumarate for antiretroviral therapy and HIV pre-exposure prophylaxis: An observational cohort study

BACKGROUND: Tenofovir disoproxil fumarate (TDF) is associated with adverse renal outcomes when prescribed for HIV infection. There are few data concerning real-world renal outcomes amongst patients prescribed TDF for pre-exposure prophylaxis (PrEP). METHODS AND FINDINGS: Data were extracted from 52...

Descripción completa

Detalles Bibliográficos
Autores principales: Heron, Jack E., McManus, Hamish, Vickers, Tobias, Ryan, Kathleen, Wright, Edwina, Carter, Allison, Stoove, Mark, Asselin, Jason, Grulich, Andrew, Donovan, Basil, Guy, Rebecca, Varma, Rick, Chen, Marcus, Ryder, Nathan, Lewis, David A., Templeton, David J., O’Connor, Catherine C., Gracey, David M.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Public Library of Science 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9955644/
https://www.ncbi.nlm.nih.gov/pubmed/36827395
http://dx.doi.org/10.1371/journal.pone.0280339
_version_ 1784894397474668544
author Heron, Jack E.
McManus, Hamish
Vickers, Tobias
Ryan, Kathleen
Wright, Edwina
Carter, Allison
Stoove, Mark
Asselin, Jason
Grulich, Andrew
Donovan, Basil
Guy, Rebecca
Varma, Rick
Chen, Marcus
Ryder, Nathan
Lewis, David A.
Templeton, David J.
O’Connor, Catherine C.
Gracey, David M.
author_facet Heron, Jack E.
McManus, Hamish
Vickers, Tobias
Ryan, Kathleen
Wright, Edwina
Carter, Allison
Stoove, Mark
Asselin, Jason
Grulich, Andrew
Donovan, Basil
Guy, Rebecca
Varma, Rick
Chen, Marcus
Ryder, Nathan
Lewis, David A.
Templeton, David J.
O’Connor, Catherine C.
Gracey, David M.
author_sort Heron, Jack E.
collection PubMed
description BACKGROUND: Tenofovir disoproxil fumarate (TDF) is associated with adverse renal outcomes when prescribed for HIV infection. There are few data concerning real-world renal outcomes amongst patients prescribed TDF for pre-exposure prophylaxis (PrEP). METHODS AND FINDINGS: Data were extracted from 52 sexual health clinics across Australia from 2009–2019. All patients prescribed TDF-containing antiretroviral therapy and PrEP were included. Rates of renal impairment (a fall in eGFR to <60 ml/min/1·73m(2)) were calculated for people living with HIV (PLWHIV) prescribed TDF and HIV negative PrEP-users. Risk factors were assessed using Cox-proportional hazards models. Sensitivity analysis of risk using 1:1 propensity-score matching to adjust for potential imbalance in HIV and PrEP cohorts was conducted. 5,973 patients on PrEP and 1,973 PLWHIV were included. There were 39 (0.7%) instances of renal impairment in the PrEP group and 81 (4.1%) in the PLWHIV cohort (hazard ratio [HR]:0.35 95% confidence interval [CI]: 0.22–0.56). Rates of renal impairment were 4.01/1000 person-years (95%CI:2.93–5.48) in the PrEP cohort and 16.18/1000 person-years (95%CI:13.01–20.11) in the PLWHIV cohort (p<0.001). Predictors of renal impairment were: older age (40–49 years (HR:5.09 95%CI: 2.12–12.17) and 50–82 years (HR:13.69 95%CI: 5.92–31.67) (compared with 30–39 years) and baseline eGFR<90ml/min (HR:61.19 95%CI: 19.27–194.30). After adjusting for age and baseline eGFR the rate of renal impairment remained lower in the PrEP cohort (aHR:0.62 95%CI: 0.40–0.94, p = 0.023). In propensity-matched analysis using 1,622 patients per cohort the risk of renal impairment remained higher in the PLWHIV cohort (log-rank p = 0.001). CONCLUSION: Patients prescribed TDF-based PrEP had lower rates of renal impairment than patients prescribed TDF for HIV infection. In propensity analysis, after matching for some risk factors, rates of renal impairment remained higher amongst patients with HIV.
format Online
Article
Text
id pubmed-9955644
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher Public Library of Science
record_format MEDLINE/PubMed
spelling pubmed-99556442023-02-25 Renal impairment associated with tenofovir disoproxil fumarate for antiretroviral therapy and HIV pre-exposure prophylaxis: An observational cohort study Heron, Jack E. McManus, Hamish Vickers, Tobias Ryan, Kathleen Wright, Edwina Carter, Allison Stoove, Mark Asselin, Jason Grulich, Andrew Donovan, Basil Guy, Rebecca Varma, Rick Chen, Marcus Ryder, Nathan Lewis, David A. Templeton, David J. O’Connor, Catherine C. Gracey, David M. PLoS One Research Article BACKGROUND: Tenofovir disoproxil fumarate (TDF) is associated with adverse renal outcomes when prescribed for HIV infection. There are few data concerning real-world renal outcomes amongst patients prescribed TDF for pre-exposure prophylaxis (PrEP). METHODS AND FINDINGS: Data were extracted from 52 sexual health clinics across Australia from 2009–2019. All patients prescribed TDF-containing antiretroviral therapy and PrEP were included. Rates of renal impairment (a fall in eGFR to <60 ml/min/1·73m(2)) were calculated for people living with HIV (PLWHIV) prescribed TDF and HIV negative PrEP-users. Risk factors were assessed using Cox-proportional hazards models. Sensitivity analysis of risk using 1:1 propensity-score matching to adjust for potential imbalance in HIV and PrEP cohorts was conducted. 5,973 patients on PrEP and 1,973 PLWHIV were included. There were 39 (0.7%) instances of renal impairment in the PrEP group and 81 (4.1%) in the PLWHIV cohort (hazard ratio [HR]:0.35 95% confidence interval [CI]: 0.22–0.56). Rates of renal impairment were 4.01/1000 person-years (95%CI:2.93–5.48) in the PrEP cohort and 16.18/1000 person-years (95%CI:13.01–20.11) in the PLWHIV cohort (p<0.001). Predictors of renal impairment were: older age (40–49 years (HR:5.09 95%CI: 2.12–12.17) and 50–82 years (HR:13.69 95%CI: 5.92–31.67) (compared with 30–39 years) and baseline eGFR<90ml/min (HR:61.19 95%CI: 19.27–194.30). After adjusting for age and baseline eGFR the rate of renal impairment remained lower in the PrEP cohort (aHR:0.62 95%CI: 0.40–0.94, p = 0.023). In propensity-matched analysis using 1,622 patients per cohort the risk of renal impairment remained higher in the PLWHIV cohort (log-rank p = 0.001). CONCLUSION: Patients prescribed TDF-based PrEP had lower rates of renal impairment than patients prescribed TDF for HIV infection. In propensity analysis, after matching for some risk factors, rates of renal impairment remained higher amongst patients with HIV. Public Library of Science 2023-02-24 /pmc/articles/PMC9955644/ /pubmed/36827395 http://dx.doi.org/10.1371/journal.pone.0280339 Text en © 2023 Heron et al https://creativecommons.org/licenses/by/4.0/This is an open access article distributed under the terms of the Creative Commons Attribution License (https://creativecommons.org/licenses/by/4.0/) , which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
spellingShingle Research Article
Heron, Jack E.
McManus, Hamish
Vickers, Tobias
Ryan, Kathleen
Wright, Edwina
Carter, Allison
Stoove, Mark
Asselin, Jason
Grulich, Andrew
Donovan, Basil
Guy, Rebecca
Varma, Rick
Chen, Marcus
Ryder, Nathan
Lewis, David A.
Templeton, David J.
O’Connor, Catherine C.
Gracey, David M.
Renal impairment associated with tenofovir disoproxil fumarate for antiretroviral therapy and HIV pre-exposure prophylaxis: An observational cohort study
title Renal impairment associated with tenofovir disoproxil fumarate for antiretroviral therapy and HIV pre-exposure prophylaxis: An observational cohort study
title_full Renal impairment associated with tenofovir disoproxil fumarate for antiretroviral therapy and HIV pre-exposure prophylaxis: An observational cohort study
title_fullStr Renal impairment associated with tenofovir disoproxil fumarate for antiretroviral therapy and HIV pre-exposure prophylaxis: An observational cohort study
title_full_unstemmed Renal impairment associated with tenofovir disoproxil fumarate for antiretroviral therapy and HIV pre-exposure prophylaxis: An observational cohort study
title_short Renal impairment associated with tenofovir disoproxil fumarate for antiretroviral therapy and HIV pre-exposure prophylaxis: An observational cohort study
title_sort renal impairment associated with tenofovir disoproxil fumarate for antiretroviral therapy and hiv pre-exposure prophylaxis: an observational cohort study
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9955644/
https://www.ncbi.nlm.nih.gov/pubmed/36827395
http://dx.doi.org/10.1371/journal.pone.0280339
work_keys_str_mv AT heronjacke renalimpairmentassociatedwithtenofovirdisoproxilfumarateforantiretroviraltherapyandhivpreexposureprophylaxisanobservationalcohortstudy
AT mcmanushamish renalimpairmentassociatedwithtenofovirdisoproxilfumarateforantiretroviraltherapyandhivpreexposureprophylaxisanobservationalcohortstudy
AT vickerstobias renalimpairmentassociatedwithtenofovirdisoproxilfumarateforantiretroviraltherapyandhivpreexposureprophylaxisanobservationalcohortstudy
AT ryankathleen renalimpairmentassociatedwithtenofovirdisoproxilfumarateforantiretroviraltherapyandhivpreexposureprophylaxisanobservationalcohortstudy
AT wrightedwina renalimpairmentassociatedwithtenofovirdisoproxilfumarateforantiretroviraltherapyandhivpreexposureprophylaxisanobservationalcohortstudy
AT carterallison renalimpairmentassociatedwithtenofovirdisoproxilfumarateforantiretroviraltherapyandhivpreexposureprophylaxisanobservationalcohortstudy
AT stoovemark renalimpairmentassociatedwithtenofovirdisoproxilfumarateforantiretroviraltherapyandhivpreexposureprophylaxisanobservationalcohortstudy
AT asselinjason renalimpairmentassociatedwithtenofovirdisoproxilfumarateforantiretroviraltherapyandhivpreexposureprophylaxisanobservationalcohortstudy
AT grulichandrew renalimpairmentassociatedwithtenofovirdisoproxilfumarateforantiretroviraltherapyandhivpreexposureprophylaxisanobservationalcohortstudy
AT donovanbasil renalimpairmentassociatedwithtenofovirdisoproxilfumarateforantiretroviraltherapyandhivpreexposureprophylaxisanobservationalcohortstudy
AT guyrebecca renalimpairmentassociatedwithtenofovirdisoproxilfumarateforantiretroviraltherapyandhivpreexposureprophylaxisanobservationalcohortstudy
AT varmarick renalimpairmentassociatedwithtenofovirdisoproxilfumarateforantiretroviraltherapyandhivpreexposureprophylaxisanobservationalcohortstudy
AT chenmarcus renalimpairmentassociatedwithtenofovirdisoproxilfumarateforantiretroviraltherapyandhivpreexposureprophylaxisanobservationalcohortstudy
AT rydernathan renalimpairmentassociatedwithtenofovirdisoproxilfumarateforantiretroviraltherapyandhivpreexposureprophylaxisanobservationalcohortstudy
AT lewisdavida renalimpairmentassociatedwithtenofovirdisoproxilfumarateforantiretroviraltherapyandhivpreexposureprophylaxisanobservationalcohortstudy
AT templetondavidj renalimpairmentassociatedwithtenofovirdisoproxilfumarateforantiretroviraltherapyandhivpreexposureprophylaxisanobservationalcohortstudy
AT oconnorcatherinec renalimpairmentassociatedwithtenofovirdisoproxilfumarateforantiretroviraltherapyandhivpreexposureprophylaxisanobservationalcohortstudy
AT graceydavidm renalimpairmentassociatedwithtenofovirdisoproxilfumarateforantiretroviraltherapyandhivpreexposureprophylaxisanobservationalcohortstudy
AT renalimpairmentassociatedwithtenofovirdisoproxilfumarateforantiretroviraltherapyandhivpreexposureprophylaxisanobservationalcohortstudy